Website update: I-app added + notice regarding daily news.

Aug 09, 2012 No Comments

Dear Readers, Some of you may have noticed recently a lack of daily news updates on the site. I can assure you that the FDA Calendar, Clinical Database and other databases have been updated and are currently running only about a day behind. However, I have been unable to post daily news updates due to […]

Read more

Pipeline profiles of recent Biotech Initial Public Offerings – DRTX TSRO HPTX MACK CCXI CEMP

Jul 28, 2012 No Comments

Hyperion Therapeutics, Inc (NASDAQ:HPTX) - Initial public offering July 2012.  PIPELINE Ravicti: PDUFA date October 23, 2012 for urea cycle disorders. Phase 2 trial completed for hepatic encephalopathy, or HE. End of Phase 2 meeting with the FDA planned for 4Q 2012. Durata Therapeutics Inc (NASDAQ:DRTX) - Initial public offering July 2012.  PIPELINE Dalbavancin: Phase 3 trial for the treatment of patients with acute bacterial skin and skin […]

Read more

SLXP PGNX issued CRL. FURX resubmits NDA. ARIA initiates Phase 3 CML. CTIC confirms possibility of reverse split + ACUR

Jul 28, 2012 4 Comments

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) and Progenics Pharmaceuticals (NASDAQ:PGNX) today received a Complete Response Letter (CRL) for its Supplemental New Drug Application (sNDA) for RELISTOR injection for subcutaneous use for the treatment of opioid-induced constipation (OIC) in adult patients with chronic, non-cancer pain. The CRL requests additional clinical data. Salix and Progenics intend to request an End-of-Review meeting with the Division […]

Read more

THR/TBGNF positive Adcom vote. AMRN and HZNP FDA Approval. SCMP files sNDA. SNTA offering. EXEL initiates Phase 2 NSCLC trial.AEZS update.

Jul 27, 2012 No Comments

ThromboGenics NV (Euronext Brussels: THR) (PINK:TBGNF) - The FDA Dermatologic and Ophthalmic Drugs Advisory Committee recommended that ocriplasmin be granted approval for the treatment of symptomatic Vitreomacular Adhesion (VMA) by a vote of 10 to 0. The PDUFA date is 17 October, 2012. Amarin Corporation plc (Nasdaq:AMRN) announced the FDA has approved Vascepa capsules (AMR101) as a treatment to reduce triglyceride levels in […]

Read more

APPA to file NDA this September. LGND PDUFA set for November. FLML NDA due this year. XNPT offering + CYTR

Jul 26, 2012 No Comments

A.P. Pharma, Inc. (OTCBB: APPA.OB) announced that it now hopes to re-file its NDA of APF530, for the prevention of both acute- and delayed-onset chemotherapy-induced nausea and vomiting, during September 2012. The company had previously given guidance of a filing during “mid-2012″. The company also said it has issued 102m shares at $0.525 per share, resulting in gross proceeds of approximately $53.6 […]

Read more

CRTX Advisory Committee date set. MAPP Levadex NDA update. ZGNX offering + updates for ITMN MDVN AEZS DVAX NKTR CADX

Jul 25, 2012 No Comments

Cornerstone Therapeutics, Inc. (NASDAQ:CRTX) – The Cardiovascular and Renal Drugs Advisory Committee will meet on September 13, 2012, to discuss the NDA of lixivaptan, for the proposed indication of the treatment of symptomatic hypervolemic and euvolemic hyponatremia associated with heart failure and syndrome of inappropriate antidiuretic hormone (SIADH), respectively. MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) said it hopes to resubmit its NDA of LEVADEX for the […]

Read more

New tool added – FDA Historical Calendar – A look back in history.

Jul 23, 2012 2 Comments

I am pleased to inform you that I have added another tool to the website. As users of the FDA Calendar may be aware, once a PDUFA catalyst has been completed the event is removed from the calendar. However, many readers have noted that they would prefer access to past FDA decisions. In light of […]

Read more

ONXX receives FDA Approval. SGEN and ASTX granted positive CHMP recommendations. ANTH and SOMX offering details + PSDV SGYP ARRY news

Jul 20, 2012 No Comments

Onyx Pharmaceuticals (Nasdaq: ONXX) today announced that it received accelerated approval from the FDA for Kyprolis (carfilzomib) for Injection, for the treatment of patients with multiple myeloma who have received at least two prior therapies, including bortezomib and an immunomodulatory agent, and have demonstrated disease progression on or within 60 days of completion of the last therapy. Ligand […]

Read more

ALIM NSPH ANTH raising cash.INFI brings forward data release. ALXA MAA update.

Jul 19, 2012 No Comments

Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), announced that it intends to offer and sell shares of its common stock in a public offering. Nanosphere, Inc. (Nasdaq: NSPH) also announced that it intends to offer shares of its common stock in a public offering. Alimera Sciences, Inc., (Nasdaq:ALIM) (Alimera) announced that will raise cash through a $40 million Series […]

Read more